ストックスクリーナーアプリを入手
22.34
0.45%
-0.10
前日終値:
$22.44
開ける：
$22.32
24時間の取引高:
1.05M
Relative Volume:
0.79
時価総額：
$14.19B
収益：
$2.89B
当期純損益:
$684.26M
株価収益率:
21.23
EPS:
1.0524
ネットキャッシュフロー:
$958.82M
1週間 パフォーマンス:
+4.88%
1か月 パフォーマンス:
+2.48%
6か月 パフォーマンス:
-18.73%
1年 パフォーマンス:
-22.83%
1日の値動き範囲:
$22.07
$22.36
1週間の範囲:
$21.30
$22.55
52週間の値動き範囲:
$18.64
$31.88
Genmab Adr Stock (GMAB) Company Profile
GMAB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
22.34 | 14.19B | 2.89B | 684.26M | 958.82M | 1.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | 開始されました | Redburn Atlantic | Buy |
| 2024-09-04 | 再開されました | Morgan Stanley | Equal-Weight |
| 2024-08-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-15 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | ダウングレード | Citigroup | Neutral → Sell |
| 2023-12-06 | アップグレード | UBS | Neutral → Buy |
| 2023-11-10 | アップグレード | Deutsche Bank | Hold → Buy |
| 2023-11-08 | アップグレード | DNB Markets | Sell → Buy |
| 2023-10-18 | 開始されました | Exane BNP Paribas | Underperform |
| 2023-09-06 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | 開始されました | BTIG Research | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-31 | 開始されました | UBS | Neutral |
| 2023-05-12 | 開始されました | Morgan Stanley | Underweight |
| 2022-12-20 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-11-14 | 開始されました | William Blair | Mkt Perform |
| 2022-11-11 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2022-06-24 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-05-02 | 開始されました | Cowen | Market Perform |
| 2022-03-16 | アップグレード | UBS | Neutral → Buy |
| 2022-01-31 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-12-01 | 開始されました | Berenberg | Sell |
| 2021-09-16 | ダウングレード | Jefferies | Buy → Hold |
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | 開始されました | Deutsche Bank | Buy |
| 2021-01-19 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | ダウングレード | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-06-25 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | 開始されました | Credit Suisse | Outperform |
| 2020-02-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-12-12 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2019-09-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-08-12 | 開始されました | Guggenheim | Buy |
| 2019-08-12 | 開始されました | Morgan Stanley | Overweight |
| 2019-08-12 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Genmab Adr (GMAB) 最新ニュース
Views of Wall Street’s Leading Experts on Genmab ADR - SETE News
What is Core & Main Inc (CNM) Stock Return on Shareholders’ Capital? - SETE News
There is no doubt that Kite Realty Group Trust (KRG) ticks all the boxes. - SETE News
Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - Yahoo Finance
Sea Ltd ADR (NYSE: SE) Jumps 4.64%, Turning Investors Away - Stocks Register
Does Genmab ADR (NASDAQ: GMAB) Still Look Hot This Week? - Stocks Register
Genmab (GMAB) Upgraded to Buy: Here's What You Should Know - MSN
GMAB vs. QGEN: Which Stock Is the Better Value Option? - MSN
Are Investors Undervaluing Genmab (GMAB) Right Now? - Yahoo Finance
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire Inc.
10 Biggest Biotechnology Companies - Investopedia
Weekly Upgrades and Downgrades - InvestorPlace
Is the Options Market Predicting a Spike in Genmab (GMAB) Stock? - Yahoo Finance
Is Genmab (GMAB) Stock Undervalued Right Now? - Yahoo Finance
GMAB or INCY: Which Is the Better Value Stock Right Now? - Yahoo Finance
Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround - Yahoo Finance
Market Resilience: Genmab ADR (GMAB) Finishes Weak at 24.14, Down -5.44 - The Dwinnex
GANDHIM.APPL Share Price Today Up 13% - Equitymaster
Glenmark Pharma Share Price Today Down 3% - Equitymaster
Post-Trade Analysis: Genmab ADR (GMAB) Climbs 1.55, Closing at 26.90 - The Dwinnex
Market Recap: Genmab ADR (GMAB)’s Negative Momentum, Closing at 27.41 - The Dwinnex
BioNTech's Loss Quadruples as COVID-19 Vaccine Demand Falls - Yahoo Finance
Wall Street Analysts Think Genmab (GMAB) Could Surge 45.08%: Read This Before Placing a Bet - Yahoo Finance
All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy - Yahoo Finance
GMAB vs. CSLLY: Which Stock Is the Better Value Option? - Yahoo Finance
RBC Capital upgrades Genmab stock amid strong pipeline prospects - Investing.com
FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma - Yahoo Finance
GMAB: 3 Biotech Stocks Gaining Altitude and Interest - StockNews.com
Genmab's 'Evolution' Continues With A $1.8 Billion Deal; But Shares Slip - Investor's Business Daily
GMAB: Bank on the Future Returns With These 3 Biotech Stocks - StockNews.com
GMAB: 3 Biotech Stocks to Boost Portfolios - StockNews.com
GMAB: 3 Biotech Stocks to Watch in November - StockNews.com
Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results - MarketWatch
Stocks Flashing Renewed Technical Strength: Ascendis Pharma ADR - Investor's Business Daily
Moderna Stock Getting Closer To Key Technical Benchmark - Inkl
GILD or GMAB: Which Is the Better Value Stock Right Now? - Yahoo News Canada
Is Elevance Health, Inc. (ELV) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue? - Yahoo Finance
Genmab's chief development officer sells shares in US - MedWatch
INCY vs. GMAB: Which Stock Is the Better Value Option? - Yahoo Finance
Should You Buy Genmab (GMAB) Ahead of Earnings? - Yahoo Finance
Inside Genmab's blockbuster IPO - IR Magazine
Pipeline of Proprietary Antibodies - flow – Deutsche Bank
Emergent BioSolutions Sees Its Composite Rating Rise To 97 - Investor's Business Daily
Genmab (GMAB) Begins Phase III Study on Cervical Cancer Drug - Yahoo Finance
The Daily Biotech Pulse: GlaxoSmithKline, IDEAYA Strike Oncology Partnership, Decision Day For Merck, Adverum's New CEO - Benzinga
Genmab's offering and listing in the USA - Bech-Bruun
Genmab AS (GMAB) Stock Price, Trades & News - GuruFocus.com
Genmab IPO: What You Need To Know - Benzinga
Genmab Adr (GMAB) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):